Loading
Medical Imaging Techniques and Applications · Journal article
Cancer · August 7, 2026
Encouraging direction, but not yet definitive.
This population-based cohort study of 3,696 breast cancer patients found that post-diagnostic bisphosphonate use for ≥1 year was associated with reduced all-cause and breast cancer-specific mortality in hormone receptor-positive breast cancer, but with increased recurrence and mortality risks in triple-negative breast cancer. The subtype-specific divergence suggests bisphosphonates may have differential efficacy or harm depending on tumor biology, requiring confirmation in prospective trials.
Population-based cohort study. Hormone receptor-positive and triple-negative breast cancer participants from a population-based cohort; median age 51 and 52 years respectively.. Intervention: Pre- and post-diagnostic bisphosphonate use, including use for at least 1 year and initiation post-diagnosis only.. Compared with: Never users of bisphosphonates.. n = 3,696.
Post-diagnostic BP use ≥1 year protective for all-cause mortality in HR+ cases (HR 0.67, 95% CI 0.49–0.93) Post-diagnostic BP use ≥1 year protective for breast cancer-specific mortality in HR+ cases (HR 0.54, 95% CI 0.33–0.89) Among TNBC cases with continued BP use post-diagnosis, increased recurrence risk (HR 3.43, 95% CI 1.67–7.07)
The harmful association in TNBC is unexpected and contradicts the stated antitumor characteristics of bisphosphonates; mechanistic explanation lacking. No report of absolute risk reduction, number needed to treat/harm, or interaction testing between BP use and hormone receptor status.
Clinicians should recognize that bisphosphonate utility in breast cancer appears to be subtype-dependent: post-diagnostic use may reduce mortality in HR+ disease but may be associated with harm in TNBC. These observational findings require validation in randomized trials before changing clinical practice, particularly for TNBC where the signal is concerning and unexpected.
Population-based cohort study with adequate sample size showing protective mortality effects in HR+ breast cancer with post-diagnostic bisphosphonates, but observational design, lack of randomization, and conflicting results in TNBC subgroup limit strength.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognize that bisphosphonate utility in breast cancer appears to be subtype-dependent: post-diagnostic use may reduce mortality in HR+ disease but may be associated with harm in TNBC. These observational findings require validation in randomized trials before changing clinical practice, particularly for TNBC where the signal is concerning and unexpected.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
BACKGROUND: Bisphosphonates (BPs) are routinely used as an adjuvant therapy for breast cancer to reduce the risk of bone recurrences given their anti-resorptive effects on bones and antitumor characteristics. However, there remains limited evidence regarding their utility across different subtypes. METHODS: In this population-based cohort study, the authors assessed the effects of pre- and post-diagnostic BP use on recurrence, any second breast cancer event, all-cause mortality (ACM), and breast cancer-specific mortality (BCSM) using multivariable-adjusted Cox proportional hazards models among hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) participants. RESULTS: This study enrolled 2260 HR+ and 1436 TNBC participants. The median age and follow-up time to death was 51 and 52 years old and 168.3 and 147 months in the two subtypes, respectively. Post-diagnostic BP use for at least 1 year was protective for ACM (hazard ratio [HR], 0.67; 95% confidence interval [CI], 0.49-0.93) and BCSM (HR, 0.54; 95% CI, 0.33-0.89) compared to never users in HR+ cases. Among participants who initiated BP after diagnosis only, a lower point estimates on the clinical outcomes were observed across both subtypes, reaching statistical significance for BCSM (HR, 0.62; 95% CI, 0.39-0.98) in HR+ cases. Among TNBC cases who continued BP use post-diagnosis, increased risks of recurrence (HR, 3.43; 95% CI, 1.67-7.07) and BCSM (HR, 2.54; 95% CI, 1.24-5.19) were observed. CONCLUSIONS: Although this study confirmed the protective effects of post-diagnostic BP use on risks of mortality among HR+ cases, further studies are required to prove the effects of post-diagnostic BP use among TNBC participants.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.